Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.
John J. Nicols, insider at Codexis

John J. Nicols Insider Information

CEO of Codexis
John J. Nicols serves as President, Chief Executive Officer, Director of Codexis, Inc. Mr. Nicols brings to our board of directors his knowledge of Codexis as its President and Chief Executive Officer and his extensive prior management experience in the chemicals industry. Prior to that time, Mr. Nicols served in various capacities at Albemarle Corporation, a public company focused on the development, manufacture and marketing of highly engineered specialty chemicals, since he joined that company in 1990. Mr. Nicols most recently served as its Senior Vice President, Strategic Development and Catalysts, from March 2012 to June 2012. Mr. Nicols previously served as its Vice President, Catalysts from January 2007 to February 2012, its Vice President, Fine Chemistry from June 2002 to December 2006, its Division Vice President, Global Flame Retardants business from February 1999 through June 2002 and its Asia Pacific Business Director for the Bromine Chemicals business, based in Tokyo, Japan, from 1995 to 1998. Prior to his time with Albemarle Corporation, Mr. Nicols worked for three years in manufacturing and research and development for Hercules, Inc. Mr. Nicols has served on the board of directors of California Life Sciences Association (formerly BayBio), a non-profit organization, since January 2014. In addition, Mr. Nicols has served on the board of directors of Solve ME/CFS Initiative, a non-profit organization, since January 2015, and currently serves as chairperson and on the executive and nominating committees of that organization. Mr. Nicols received a B.S. in Chemical Engineering from the Polytechnic Institute of New York University and an M.B.A. from the Sloan School of Management at the Massachusetts Institute of Technology.

What is John J. Nicols' net worth?

The estimated net worth of John J. Nicols is at least $10.73 million as of May 12th, 2022. Mr. Nicols owns 1,022,679 shares of Codexis stock worth more than $10,727,903 as of May 22nd. This net worth estimate does not reflect any other investments that Mr. Nicols may own. Additionally, Mr. Nicols receives an annual salary of $1,170,000.00 as CEO at Codexis. Learn More about John J. Nicols' net worth.

How old is John J. Nicols?

Mr. Nicols is currently 58 years old. There are 2 older executives and no younger executives at Codexis. Learn More on John J. Nicols' age.

What is John J. Nicols' salary?

As the CEO of Codexis, Inc., Mr. Nicols earned a total compensation package of $2,960,857.00 in 2020. Mr. Nicols earned a salary of $686,667.00, a bonus of $168,188.00, options awards of $1,795,800.00, non-equity compensation of $297,562.00, and other compensation of $12,640.00. Learn More on John J. Nicols' salary.

How do I contact John J. Nicols?

The corporate mailing address for Mr. Nicols and other Codexis executives is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. Codexis can also be reached via phone at (650) 421-8100 and via email at [email protected] Learn More on John J. Nicols' contact information.

Has John J. Nicols been buying or selling shares of Codexis?

In the last ninety days, John J. Nicols has sold $396,935.00 in Codexis stock. As far as recent transactions, on Sunday, May 22nd, 0 shares of BMO Capital Markets stock. Learn More on John J. Nicols' trading history.

Who are Codexis' active insiders?

Codexis' insider roster includes Byron Dorgan (Director), Bernard Kelley (Director), John Nicols (CEO), Dennis Wolf (Director), and Patrick Yang (Director). Learn More on Codexis' active insiders.

Are insiders buying or selling shares of Codexis?

In the last year, insiders at the biotechnology company sold shares 9 times. They sold a total of 175,000 shares worth more than $4,149,600.00. The most recent insider tranaction occured on May, 12th when CEO John J Nicols sold 38,500 shares worth more than $396,935.00. Insiders at Codexis own 7.5 % of the company. Learn More about insider trades at Codexis.

Information on this page was last updated on 5/12/2022.

John J. Nicols Insider Trading History at Codexis

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/12/2022Sell38,500$10.31$396,935.001,022,679View SEC Filing Icon  
3/10/2022Sell38,500$18.93$728,805.00View SEC Filing Icon  
11/10/2021Sell35,000$40.29$1,410,150.00View SEC Filing Icon  
5/18/2021Sell70,385$18.45$1,298,603.25
8/20/2019Buy10,000$13.30$133,000.001,082,679View SEC Filing Icon  
3/19/2019Sell55,072$20.83$1,147,149.761,087,751View SEC Filing Icon  
12/7/2018Sell43,812$21.78$954,225.361,112,679View SEC Filing Icon  
9/28/2018Sell80,000$17.57$1,405,600.001,112,679View SEC Filing Icon  
8/15/2018Sell14,259$15.14$215,881.261,084,538View SEC Filing Icon  
6/11/2018Sell9,007$15.18$136,726.261,079,886View SEC Filing Icon  
6/8/2018Sell7,207$15.35$110,627.451,079,886View SEC Filing Icon  
3/23/2018Sell22,465$11.57$259,920.051,078,990View SEC Filing Icon  
3/8/2013Buy27,000$2.42$65,340.00View SEC Filing Icon  
3/7/2013Buy54,000$2.22$119,880.00View SEC Filing Icon  
See Full Table

John J. Nicols Buying and Selling Activity at Codexis

This chart shows John J Nicols's buying and selling at Codexis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Codexis Company Overview

Codexis logo
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $10.49
Low: $9.88
High: $10.84

50 Day Range

MA: $16.13
Low: $9.70
High: $21.89

2 Week Range

Now: $10.49
Low: $9.47
High: $42.01

Volume

652,236 shs

Average Volume

1,048,133 shs

Market Capitalization

$685.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.96
Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.